Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Influence of Remicade (infliximab) in the skin proteome of psoriatic patients
2009-013869-26Phase 4Terminated
- Sponsor
- Associação para o Desenvolvimento da Dermatologia do Hospital de Santa Maria
- Start
- Aug 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of infliximab in psoriasis, sponsored by Associação para o Desenvolvimento da Dermatologia do Hospital de Santa Maria. Primary endpoints: PASI 75 response at week 12 and Proteomic comparison of lesional and non-lesional skin. Started Aug 2009; status: terminated.
02
Drugs
infliximab
03
Conditions
psoriasis
Beyond the preview
Go deeper on 2009-013869-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-013869-26.